Edward Thompson, CPA – Chief Financial Officer
As CFO, Ed provides strategic direction for the financial growth and management of PeriGen. He is responsible for managing all aspects of Finance and Accounting, Legal, and HR to ensure the company’s growth, efficiency and financial integrity.
Ed’s experience includes accounting and financial leadership roles in medical devices and biotechnology companies in various funding stages ranging from Series A through Series D, with experience in process improvement, systems implementation, and M&A activities. Prior to joining PeriGen, Ed served as Controller and Interim-CFO for Asklepios BioPharmaceutical, where he served as a key member of the executive team through a period of significant growth, and successful fundraising of $235 million in outside investment. Prior to Asklepios BioPharmaceutical, Ed was the Corporate Controller for TearScience from 2016 through 2018, where he guided the company through an acquisition by Johnson & Johnson. At both companies, Ed’s experience included financial planning and analysis, supporting sales and implementation teams, communicating with investors, and managing outside supporting resources such as legal, audit and tax.
Before joining TearScience, Ed began his career as an auditor with PriceWaterhouseCoopers, and later, Grant Thornton. Ed is a graduate of the University of South Carolina’s Moore School of Business, where he earned a BS in Business Administration and Masters in Accountancy.